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 ABSTRACT 
The landscape of HPV infection in racial/ethnic subgroups of head and neck cancer 
(HNC) patients has not been evaluated carefully. In this study, a meta-analysis 
examined the prevalence of HPV in HNC patients of African ancestry. Additionally, a 
pooled analysis of subject-level data was also performed to investigate HPVprevalence 
and patterns of p16 (CDNK2A) expression amongst different racial groups.Eighteen 
publications (N = 798 Black HNC patients) were examined in the meta-analysis, and the 
pooled analysis included 29 datasetscomprisedof 3,129HNC patients of diverse 
racial/ethnic background.The meta-analysis revealed that the prevalence of HPV16 was 
higher among Blacks with oropharyngealcancer than Blacks with non-oropharyngeal 
cancer. However, there was great heterogeneity observed among studies (Q test 
P<0.0001). In the pooled analysis, after adjusting for each study, year of diagnosis, age, 
gender and smoking status, the prevalence of HPV16/18 in oropharyngeal cancer 
patients was highest in Whites (61.1%), followed by 58.0% in Blacks and 25.2% in 
Asians (P<0.0001). There was no statistically significant difference in HPV16/18 
prevalencein non-oropharyngeal cancer by race (P=0.682). With regard to the pattern of 
HPV16/18 status and p16 expression, White patients had the highest proportion of 
HPV16/18+/p16+ oropharyngeal cancer (52.3%), while Asians and Blacks had 
significantly lower proportions (23.0% and 22.6%, respectively) [P <0.0001]. Our 
findings suggest that thepattern of HPV16/18status and p16 expressionin 
oropharyngeal cancer that appears to differ by raceand this may contribute to survival 
disparities by race. 
  
Introduction 
 
Head and neck cancer (HNC) is the sixth most common cancer in the world, 
accounting for approximately 4% of all cancer cases(1). In 2012, there were an 
estimated 599,637 new cases of cancer of the oral cavity, larynx and oropharynx, and 
324,794 deaths attributed to the disease worldwide(1). Although tobacco and alcohol 
use are the primary risk factors for developing HNC, human papillomavirus (HPV) is 
also an established risk factor for cancers arising in the oropharynx (2;3). Recently, 
HPV has also been reported to be associated with a subset of oral cavity cancers (4;5), 
but an etiological role has not been clearly demonstrated.  
A recent review and meta-analysis from our group ofhead and neck cancer 
survival in relation to HPV demonstrated a survival advantage for all HPV-positive 
patients(6), but the survival advantage was only significant for patients with cancer of 
the oropharynx. Compared to patients with HPV-negative oropharyngeal cancer, the 
risk of death and risk of recurrence for patients with HPV-positive oropharyngeal cancer 
was reduced by ~28% and ~49%, respectively. In the United States (US), a clear 
disparity in HNC survival has been reported between Black and White patients, 
particularly for oropharyngeal cancers. Poor survival rates for Black Americans 
compared to White Americans have been observed(7),and some studies have 
suggested that this disparity may be explained at least partially by a difference in 
prevalence of HPV infection(8-10). Comparisons of HPV prevalence in cancer of the 
oral cavity and larynx between variousracial/ethnic populations have been reported in a 
recent meta-analysis (11). However, a summary of HPV prevalence for Black patients 
was only reported for oral cavity cancerin this study(11). Furthermore,anassessment of 
attributed survival differences for oropharyngeal cancer between racial/ethnic 
populations was not conducted. 
The goal of the present study was to develop a more complete perspective of the 
landscape of HPV infection in ethnic subgroups of head and neck cancer patients by 
examining the published literature. We conducted a meta-analysis examining the 
prevalence of HPV in the Black population. We also performed a pooled analysis of 
cases reporting HNC and HPV status using subject-level data from the published 
literature to investigate HPV segregation and prevalence amongst different ethnic 
groups. 
 
Materials and methods 
This study was approved by the Fox Chase Cancer Center Institutional Review 
Committee.   
Literature review and data collection 
A PubMed search was conducted (from inception to December 2014) using the 
search terms, ("human papillomavirus"[All Fields] OR"HPV"[All Fields]) AND 
("squamous cell carcinoma"[All Fields] OR "cancer"[All Fields]) AND 
("oropharyngeal"[All Fields] OR "oropharynx"[All Fields] OR "head and neck"[All Fields] 
OR "tonsil"[All Fields]). All abstracts and full text of articles from the PubMed search 
were reviewed independently by two reviewers. When there was a discrepancy between 
reviewers, a third reviewer evaluated the article(s) to resolve the discrepancy. All 
studies that tested for the presence of HPV in head and neck cancer tissues from 
patients diagnosed with squamous cell carcinoma of the head and neck (oral cavity, 
oropharynx, larynx and hypopharynx) were eligible for inclusion in this analysis.The 
bibliographies of several review articles were also examined in order to identify 
additional publications that might have been missed by our PubMed search(11-15). This 
review identified291 original articles that qualified conditionally for the analysis. Studies 
that used serology methods to detect HPV antibodies were excluded from the analysis, 
as this method does not identify which tissue is infected by HPV. Studies that primarily 
evaluated HPV in lip cancers were excluded from this analysis, with the exception of 
studies where it was impossible to distinguish lip cancer data from the other head and 
neck subsites. In addition, case reports and studies that included only HPV-positive 
head and neck cancer tumors/patients were excluded. Additional exclusion criteria 
includes studies of HNC patients who were co-infected with other diseases, such as 
HIV;studies in which the cancer tissues were sampled via cyto-brushing and not biopsy 
or surgery;studies that classified HNC as HPV-related or HPV non-related tumors based 
on tumor site without directly testing that tissue for HPV;studies in which fewer than 
80% of the eligible cases were tested for HPV; and studies that selected patient 
samples non-randomly, butapplied pre-defined criteria for patient inclusion(e.g., patients 
with undifferentiated carcinoma only, metastasis only, positive lymph nodes only, 
advanced stage only, patients who underwent a specific treatment regimen, studies 
where smoking and drinking patient tissues were matched with nonsmoker and 
nondrinker patient tissues, etc.). For overlapping studies, the publication with the largest 
population and/or more complete information was included in this analysis.After 
accounting for these inclusion and exclusion criteria, 140 articles with data for all 
racial/ethnic populations were eligible for inclusion in this study. Of these, only 18 
articles presented data that could be abstracted and were included in the meta-analysis 
of Black cancer patients. All 140 articles were eligible for inclusion in the pooled 
analysis. A flow diagram of study selection is illustrated in Figure 1. 
Meta-analysis of Black HNC patients. From each of the 18 articles that included data 
from Black HNC patients (818 cases), information on the number of patients, HPV 
prevalence, HPV genotype, tumor subsite, mean age, year of cancer diagnosis, 
geographic location of the study, tissue source, HPV test methodology and HPV-
infected cancer site were extracted and tabulated.All data were abstracted 
independently by two reviewers and cross-referenced to confirm that there were no data 
entry errors. Three studies that included data for fewer than 10 Black patients(16-18) 
were therefore excluded from the meta-analysis, leaving 15 studiesincluding 798 cases. 
Pooled analysis.All investigators from the 140 studies were invited to submit their 
subject-level data for this pooled analysis;data from 22 studies were obtained.The 
remaining study investigators either did not respond or did not wish to participate. 
Common data elements included in the pooled analysis were HPV test method, HPV 
status, HPV genotype, DNA source, geographic location of the study, age at diagnosis, 
gender, race/ethnicity, p16 status, tobacco and alcohol use, clinical variables (such as 
tumor site, histology and stage) and survival variables (such as vital status and follow-
up time). Seven additional articles reported demographic, clinical, HPV results, tobacco, 
alcohol and survival data in the publications, which enabled us to create pseudo-
datasets for inclusion in the pooled analysis. All patients included in this analysis were 
diagnosed with cancers of the oral cavity, oropharynx, or larynx. Patients with 
hypopharyngeal cancers were grouped with the patients with cancers of the larynx. 
Patients with metastases or unknown primaries were excluded from this analysis. In 
total, there were 29datasets including a total of 3,129 head and neck cancer cases. 
Statistical Analysis 
The Meta-proportion of any HPV and HPV16 only was calculated for all HNC subsites 
combined as well as separately for oropharynx and non-oropharynx data. All statistical 
analyses were performed using Intercooled STATA SE (version 10) software 
(StataCorp. LP, College Station, TX). Meta-analyses of the proportion of HPV-positive 
HNC were performed using the metaprop command in STATA. HPV proportions were 
calculated for each individual study and the reported confidence intervals were based 
on Clopper-Pearson exact binomial procedures(19).Pooled proportions of the multiple 
studies were estimated using a random effects model. The Meta-prevalence estimates 
were calculated by multiplying the Meta-proportion and confidence interval values by 
100. The Q-statistics were used to test for heterogeneity between the studies included 
in the meta-analyses. The I2 metric was also calculated to quantify variation between 
studies(20). Large between-study variation was observed when the I2 values were ≥50% 
while moderate between-study heterogeneity was denoted by I2 values between 25-
50%.Evidence of publication bias or small study effects (p<0.05) was assessed using 
the Egger’s test(21).  
 
Áthelyezve (beillesztés) [1]
Törölt: A random effects model was 
used to calculate the proportion of 
HPV-positive patients when 
heterogeneity was observed (i.e., Q-
test P <0.05). 
Feljebb helyezve [1]: The Q-
statistics were used to test for 
heterogeneity between the studies 
included in the meta-analyses. A 
random effects model was used to 
calculate the proportion of HPV-positive 
patients when heterogeneity was 
observed (i.e., Q-test P <0.05). 
For the pooled analysis, unequal variance in age was observed between 
categories of race.Therefore, a square root transformation of age at diagnosis was 
performed. Adjusted HPV prevalence and 95% confidence intervals for each 
racial/ethnic group was calculated from logistic regression estimates for HPV-positive 
status, adjusting for study, year of diagnosis, square root of age, sex, history of alcohol 
drinking, and smoking history.The adjusted prevalence refers to the average HPV 
prevalence while averaging the values of the covariates in the regression model. The 
logistic coefficients and standard errors are provided in Supplementary Materials. 
ALikelihood Ratio chi-square test was performed to evaluate differences between the 
adjusted prevalence according to race and an analysis of variance (ANOVA) was used 
to comparethe mean square root of age at diagnosis between racial groups (p-values 
for pairwise comparisons were Bonferroni adjusted). P-values<0.05 were considered 
statistically significant. Mean age at diagnosis for each stratum was back transformed 
and reported. Follow-up time for overall survival refers to the interval between date of 
diagnosis and the date of last contact (if the patient was alive) or date of death.Hazard 
ratios (HR) were calculated and adjusted for each study and other confounders for risk 
of death or risk of disease progression (i.e., disease persistence, recurrence and/or 
metastasis).HR<1.0 represents an overall survival benefit and HR>1.0 represents poor 
overall survival. 
 
Results 
 
Meta-analysis, description of studies 
 Table 1 summarizes all published studies from which data were available to 
estimate HPV (any HPV or HPV16) prevalence in Black populations. Study size ranged 
from 13 to 161 patients. The majority (13/15, 87%) of studies includedPolymerase 
Chain Reaction (PCR)-based methods to test for the presence of HPV DNA. For all site 
strata (all head and neck, oropharynx and non-oropharynx), large heterogeneity was 
observed between the studies (Q test p-value range from 0.000-0.048; I2 values range 
from 62.1%-94.6%). Nevertheless, as expected, the prevalence of any HPV or HPV16 
was higher among oropharyngeal cancer patients (any HPV: 31.5%, 95% CI = 17.7-
47.1; HPV16: 45.7%, 95% CI = 25.5-66.6) in comparison to non-oropharyngeal cancer 
patients (any HPV: 14.5%, 95% CI = 1.4-36.0; HPV16: 1.1%, 95% CI = 0.0-6.0). There 
was no evidence of publication bias or small study effect. The reasons for underlying 
heterogeneity were explored by stratifying the dataset according to geographic region 
(Sub-Saharan Africa vs. US) as well as HPV test methods (ISH vs. PCR/RT-PCR). 
Large heterogeneity remained when stratified by HPV test method (data not shown). 
When stratified by geographic region (see Supplementary Table 1), large heterogeneity 
was still observed except when data were limited to HPV16 infections only. For all head 
and neck subsites combined, the meta-prevalence of HPV16 in patients from Sub-
Saharan Africa (N = 4 studies) was 1.0% (95% CI = 0.0-3.9), Q test p-value was 0.129, 
I2 was 47.0%. Large heterogeneity was still observed between the remaining eight 
studies that included patients from the US (Q test P<0.0001, I2 = 89%). Further 
stratification of the Sub-Saharan Africa studies according to head and neck subsite 
resulted in a meta-prevalence of HPV16 in non-oropharyngeal cancers at 0.1% (95% CI 
= 0.0-1.8, Q test p-value = 0.768, I2 = 0.0%). The only study in the US that reported 
HPV16 data for non-oropharyngeal cancer showed a higher prevalence (13.6%, 95% CI 
= 1.9-31.7) than that of patients in Sub-Saharan Africa. There were no studies in Sub-
Saharan Africa that reported data for HPV16 in oropharyngeal cancer patients and the 
large heterogeneity remained for the US studies that reported HPV16 data in Black 
oropharyngeal cancer patients. 
Pooled analysis, description of studies  
There were a total of 3,129patients included in this analysis (Table 2). Variations 
among the 29 studies were noted with regard to study size, the geographic region 
where the study was conducted, tumor site, and the tissue source. Studiesvaried in size 
from 15 to 489 patients and were conducted mostly in Europe (48%, 14/29 studies), 
followed by the US (31%, 9/29), Asia (17%, 5/29) and a single study in Australia. Most 
of the studies (65%, 19/29) involved patients diagnosed with cancers at both 
oropharyngeal and non-oropharyngeal sites (oral cavity, larynx, hypopharynx and non-
oropharyngeal sites not otherwise specified). The remaining studies included patients 
diagnosed with oropharyngeal cancers only. Formalin-Fixed Paraffin-Embedded (FFPE) 
tissues were examined in 66% of studies to test for the presence of HPV, rather than 
Fresh Frozen (FF) or Fresh Tissue (FT). All except for four studies used PCR 
methodology to detect HPV DNA, using either consensus or type-specific primers, and 
of these, five also evaluated HPV status using DNA in situ hybridization combined with 
PCR. Two studies detected HPV RNA using only RT-PCR and the other two detected 
both HPV RNA and DNA using RT-PCR and PCR. CDKN2A (p16) expression was 
evaluated in 16 studies using immunohistochemistry. With regard to race/ethnicity, the 
pooled dataset was diverse with patients representing African, African American, Asian 
and Whitepopulations. There was one study that included Aboriginal Australian patients. 
These patients were combined with the African and African American patients and 
classified as Black.There were 82 patients classified as other race (for 63 patients race 
was unknown and 19 patients included Pacific Islander, Middle Eastern, Indian, 
Hispanic or other not otherwise specified). These patients were grouped and classified 
as other race. Follow-up timewas available for 19 studies and ranged from 0.03 to 244.5 
months with a mean follow-up of 41.7 months and a medianfollow-up of 30.6 months. 
Prevalence of HPV16 and HPV18 according to race and head and neck subsite 
 The prevalence of HPV16 and/or HPV18 (HPV16,18)stratified by race was 
calculated for all head and neck cancers, oropharyngealcancers only and non-
oropharyngealcancers only after adjusting for study, year of diagnosis, age, gender, 
alcohol drinking, and smoking status (Table 3,and Supplementary Table 2 which 
summarizes the logistic coefficients and standard errors). As expected, the overall 
mean age for HPV-positive patients diagnosed with oropharyngeal cancers was 
lowerthan the mean age of HPV-positive patients diagnosed with non-oropharyngeal 
cancers irrespective of whether the patient carried HPV16 or HPV18 in their tumor. The 
mean age at diagnosis was 56.3 years for HPV16,18+ oropharyngealcancer patients, 
was 60.1 years for HPV16,18+ non-oropharyngeal HNC patients (p<0.0001). There was 
no statistically significant difference in the mean age at diagnosis of HPV16,18+ 
oropharyngealcancer patients according to race. However, for non-oropharyngeal head 
and neck cancer patients, Bonferroni post-hoc test shows that Asians were statistically 
significantly older compared to Whites (HPV16,18: Asians, 64.1 years vs. Whites, 54.9 
years, P = 0.038).  
 As expected, the prevalence of HPV16,18 was higher in oropharyngeal cancer 
tissues compared to non-oropharyngeal cancer tissues (HPV16,18:48.7% vs. 18.2%). 
HPV16 was the predominant genotype carried in all patient tissues, 46.6% of 
oropharyngeal cancer patients and 13.4% of non-oropharyngeal head and neck cancer 
patients were positive for this genotype. In contrast, only approximately 1-2% of patients 
carried HPV18, irrespective of whether the cancer was diagnosed in the oropharynx or 
at a non-oropharyngeal head and neck site.  
For oropharyngeal cancers, there was a statistically significant difference in the 
prevalence of HPV16,18 according to race. White patients had the highest prevalence 
of HPV16,18+ cancers followed by Blacks then Asians, however, only the prevalence in 
Asian patients was statistically significantly lower (61.1% vs. 58.0% and 25.2%, 
respectively; P <0.0001). A similar pattern was observed for the prevalence of HPV16 
infections. However, for HPV18, Black patients had the highest prevalence 
(14.8%)compared to Asians (1.6%) and Whites (1.1%) and this difference was 
statistically significant (P = 0.0025). For the non-oropharyngeal cancer patients, there 
was no statistically significant difference in HPV16 and/or 18 prevalence according to 
race. 
Expression of p16 and HPV16,18 DNA according to race in oropharynx cancer patients 
 Twelve studies (1,397 patients) presented with bothHPV16,18 and p16 data. 
Among oropharyngeal cancer patients,the pattern of combined HPV16,18 and p16 
status differed according to race, and this difference was statistically significant (Figure 
2A, p<0.0001). White patients had the highest proportion of cancers that were 
HPV16,18+/p16+ (52.3%). In contrast,Asian and Black patients had lower proportions of 
tumors with HPV16,18+/p16+ cancers (23.0% and 22.6%, respectively). In addition, 
Black patientshad a higher proportion of cancers that were HPV16,18+,but p16- 
compared to Asian and White patients (31.1% vs. 10.5% and 4.7%, respectively). The 
proportion of patients with HPV16,18-/p16- disease also differed significantly by race. 
Asian patients had the highest proportion of HPV16,18-/p16- cancers, in contrast to 
Black and White patients (66.8% vs. 37.7% and 29.6%, respectively).  
 When the oropharyngealcancer patients were stratified according to smoking 
history,the pattern of combined HPV16,18 and p16 statusaccording to race co-
segregated with the fraction of patients that were ever smokers (Figure 2B). Among 
never smokers (Figure 2C), as expected, patients with HPV16,18+/p16+ cancers 
comprised the predominant fraction among Asian, Black and White patients. However, 
White patients still had the highest proportion, and Asian patients had the lowest (White: 
80.1%, Black: 62.5% Asian: 39.6%, p<0.0001). Even among never smokers, 
Asianscontinued to have the largest proportion of patients with HPV16,18-/p16-cancers 
(37.4%), which was almost equal to the proportion of HPV16,18+/p16+ cancers 
(39.6%)observed in this subgroup. 
Predictors of overall survival for oropharyngeal cancer patients according to race 
Independent predictors of overall survival for oropharyngeal cancer patients were age at 
diagnosis, smoking history, late stage (III/IV) at diagnosis, and combined HPV16,18 and 
p16 status (Table 4). Patients with HPV16,18-/p16+ cancers had an increased risk of 
death compared to patients with HPV16,18+/p16+ oropharyngeal cancers. There was 
Törölt: All p16- patients, irrespective of 
HPV status, had a greater than three-
fold increased risk of death compared 
to patients with HPV16,18+/p16+ 
oropharyngeal cancers. 
Törölt: also 
Törölt:  near two-fold
also an even greater increased risk of death for patients with p16- cancers irrespective 
of HPV status. When stratified according to smoking history, among never smokers, 
HPV16,18-/p16-patients were the only group with a statistically significantly increased 
risk of death compared to HPV16,18+/p16+patients (Hazard Ratio[HR]: 2.70, 95% 
Confidence Interval[CI] 1.12-6.51). Patients with HPV16,18+/p16- orHPV16,18-
/p16+oropharyngeal cancers also had an increased risk of death compared to patients 
with HPV16,18+/p16+ oropharyngeal cancers, but the hazard ratios were not 
statistically significant. When stratified according to race, non-White patients differed in 
comparison to White patients regarding risk of death based on HPV16,18/p16 status. 
Table 4 shows that p16 status rather than HPV DNA status appeared to be a predictor 
of overall survival for non-White patients, but not for White patients. For non-Whites, the 
risk of death was statistically significantly increased for patients with p16-negative 
oropharyngeal cancers, irrespective of HPV16,18 status (HPV16,18+/p16-: HR = 2.95, 
95% CI = 1.60-5.42,HPV16,18-/p16-: HR = 3.11, 95% CI = 1.97-4.92 vs.HPV16,18-
/p16+: HR = 0.69, 95% CI = 0.24-2.01). In contrast,the risk of death for White patients 
with p16+ cancers was dependent upon HPV16,18 status. White patients with 
HPV16,18-/p16+ oropharyngeal cancers had an increased risk of death (HR = 2.91, 
95% CI = 1.72-4.92) in comparison to White patients with HPV16,18+/p16+ 
oropharyngeal cancers. 
The risk of disease persistence, recurrence or metastasisbased on 
HPV16,18/p16 status differed between White and non-White oropharyngeal cancer 
patients and is presented in Table 5. White patients that did not have HPV16,18+/p16+ 
disease had anincreased risk of disease persistence and/or recurrence in comparison to Törölt: two to three-fold 
patients diagnosed with HPV16,18+/p16+ disease. In contrast non-white patients with 
HPV16,18-/p16- were the only subgroup with a greater risk of disease persistence 
and/or recurrence in comparison to HPV16,18+/p16+ disease (HR = 2.70, 95% CI = 
1.52-4.82). The risk of metastasis was only associated with non-White patients carrying 
HPV16,18-/p16- oropharyngeal cancers.   
 
Discussion  
 
This study expands on our prior reported meta-analysis of HPV and HNC(6). In 
that study, we showed that the presence of HPV infection, specifically in the oropharynx 
had a significant effect on disease-free survival and overall survival. Since the time of 
that publication, HPV-positive squamous cell carcinoma of the oropharynx has been 
well described and reported as a distinct clinical entity. Oropharyngeal cancer patients 
are often non-smokers, male, younger and White compared to traditional substance 
abuse-related (tobacco and alcohol) head and neck cancer.  A dramatic increase in 
oropharyngeal cancerprevalence has been identified over the last decade (2;22;23).  
The number of cases of oropharyngeal cancer exceeded the number of cervical cancer 
cases in 2010 in the United States, and the number of HPV+oropharyngeal cancer is 
expected to exceed the incidence of cervical cancer by 2020(2). In addition, the more 
favorable outcome of HPV+oropharyngeal cancer is well-documented and has been 
confirmed in multiple studies (24;25). These tumors appear to be HPV-related, and a 
hallmark of favorable tumors is p16-positivity. 
 For unclear reasons, the prevalence and favorable outcome of 
HPV+oropharyngeal cancer is seen mostly in Whites.Variations inthe prevalence of 
HPV have been noted previously in studies of Black patients with oropharyngeal 
cancer,where some report lower prevalence and others report a prevalence that is 
higher and/or comparable to White oropharyngeal cancer patients(9;10;26). In the first 
part of this study, the meta-analysis of published HPV prevalence and HNC in Black 
patients echoes these findings. Consistent with what is expected when comparing HPV 
prevalence in oropharyngeal and non-oropharyngeal cancer subsites, we show that for 
Black patients,cancers in the oropharynx have a higher prevalenceof HPV16 (45.7%), 
than non-oropharyngeal sites (14.5%). There was large heterogeneity between the 
studies included in our meta-analysis. It is possible that differences in the HPV detection 
methods used in different studies may have influenced HPV positivity rates. For 
example, DNA ISH assays lack sensitivity and in general, PCR may lack specificity for 
transcriptionally active virus. Nevertheless, we observed that the meta-prevalence of 
HPV16among Black patients is similar to the prevalence reported in our pooled analysis 
(i.e. higher in the oropharynx and lower in non-oropharyngeal sites).  
We performed a pooled analysis of published HPV and HNC data in racial/ethnic 
subgroups in order to obtain a broader perspective. HPV status was obtained 
predominantly by PCR on FFPE tissues. Evaluation of HPV16, HPV18, and HPV16,18 
prevalence by subsite and race yielded multiple findings. First, it is clear that HPV, 
specifically HPV16 or HPV18 within the oropharynx is most common in Whites (61%). 
There is a similar yet lower rate of HPV16,18+ disease in Blacks (58%) and a significant 
difference in the rate of HPV16,18+disease in Asians (25%). This highlights the major 
Törölt: ; therefore, the reported meta-
prevalence must be interpreted with 
caution
HPV prevalence difference betweenWhites and Asians.This finding is curious, since the 
prevalence of HPV in Black patients has been reported to be statistically significantly 
lower than what has been reported for White patients in the literature (22;27). However, 
our pooled analysis reflects data from multiple institutions which is more reliable than a 
single study. The observed differences in HPV prevalence between Asians and Whites 
is also interesting and is not consistent with the previously reported meta-analysis(11). 
This inconsistency might be explained by differences in the type of Asian populations 
included in our study. This pooled analysis only included Asians from Taiwan (China) 
and Japan while the previously published meta-analysis, included Asian populations 
from China and Korea. Significantly higher HPV prevalence was observed in Korean 
patients compared to Chinese patients and could explain the higher prevalence of 
HPV+ oropharyngeal cancer in Asians in that review(11).  
An unexpected finding was the higher prevalence of HPV18 amongst Blacks.  
While HPV18 is rarely reported at either oropharyngeal (1.1%) or non-oropharyngeal 
cancer sites (1.5%) in Whites, HPV18 is nearly fifteen times more frequently detected in 
Blackoropharyngeal cancer patients. This major difference was unexpected. It is unclear 
if this is due to a higher rate of HPV18 infection in HNC in Blacks or a lower rate of 
HPV16+ oropharyngeal cancer in Blacks, thereby unmasking HPV18. 
To better characterize oropharyngeal cancers, we evaluated by both HPV and 
p16 status. Canonical HPV oropharyngeal cancer is characterized by a HPV+/p16+ 
signature and p16 status has been reported previously as the best prognostic marker 
for this disease (24;28). Oropharyngeal cancer that develops in White nonsmokers is 
mostly likely to be HPV-associated. Our study confirmed this finding; nearly 80% of 
White nonsmokers were HPV+/p16+ (Figure 2C). As p16 loss is associated with 
smoking(29), amongst ever smokers, amuch higher incidence of p16- disease was 
reported in all races. Although approximately 45% of ever smokers continue to be 
HPV+/p16+, only half that frequency of HPV+/p16+ is reported in non-Whites. Amongst 
Blacks and especially Asians, HPV-/p16+ disease comprises the majority of 
oropharyngeal disease, in distinction to Whites, where HPV+/p16+ disease is the 
predominant disease. 
While it is not surprising that patients with HPV-/p16+ oropharyngeal cancer have 
a higher risk of death compared to patients with HPV+/p16+ oropharyngeal cancer, it 
was interesting to note that among non-Whites, the risk of death for patients with HPV-
/p16+ oropharyngeal cancer was not different from patients diagnosed with HPV+/p16+ 
oropharyngeal cancer (HPV16,18-/p16+ Hazard Ratio: 0.69, 0.24-2.01). Unlike Whites 
(HPV16,18-/p16+ Hazard Ratio: 2.91, 1.72-4.92), the survival benefit among non-
Whites appears to be attributed to p16 status rather than HPV.InWhites, the survival 
benefit appears to be attributed to HPV status rather than p16 status. However, it is 
possible that HPV16,18-/p16+ oropharyngeal cancers in non-Whites may be attributed 
to other high-risk HPV types. Further investigation of the possible role of high-risk HPV 
types other than HPV16,18 in non-White oropharyngeal cancer patients is 
needed.Overall, our findings suggest that the difference in HPV/p16 patterns according 
to race may impact survival differently. Given the multifactorial cause of racial survival 
disparities, such as poor socioeconomic status and poor access to care, the effect of 
HPV/p16 patterns on racial disparities in survival is not easily identified and further 
investigations are needed.  
A limitation of this study is the use of publicationsas the source of patient data. 
Unlike database data, like SEER or The National Cancer Database, published data 
represent a sampling of the true population. A major assumption of our pooled analysis 
is that the landscape of the published literature is representative of the population as a 
whole. Given the dramatic differences noted in survival here between Whites and non-
Whites, we feel it is highly unlikely that an error in sampling of the literature can explain 
these differences. A high fraction of cells with expression of p16 in both the nucleus and 
cytoplasm is the only good correlation with prognosis and with high-risk HPV mRNA. 
For each of the studies included in the pooled analysis, we did not have detailed 
information on the cutoffs used to define p16 status (i.e., fraction of p16 expression in 
nuclei vs.cytoplasm). This is also a limitation of our study, as this detail may have 
provided more accurate correlations of p16 expression and outcome according to race.  
The reasons for this difference in patterns of HPV/p16 in oropharyngeal cancer 
are unclear. While smoking status has predicted p16 status(29), even amongst never 
smokers in this study, the prevalence of HPV+/p16+ disease is lower in non-Whites. 
Possible explanations include genetic and environmental causes. The development of 
HPV+oropharyngeal cancer has been associated with differences in sexual behavior 
patterns and marijuana use (31). Differential sexual and behavior patterns amongst 
Whites vs. non-Whites have not been studied well. While the number of oral sex 
partners has been identified in the risk of developing HPV+ oropharyngeal cancer (31).  
The percentage difference in ever oral sex partners in individuals 45-60 years old 
between Whites and Blacks appears modest (about 15% difference in prevalence) from 
a few major studies(32;33), but this remains an area of active research. Other potential 
explanations are genetic differences between races and differences in the host 
response to HPV infection,which merit further investigation. Intratypic variation of 
HPV16 is associated with geographical distribution and may contribute to differences in 
outcome(34-39). For example, African and Asian-American intratypic variants of HPV16 
show higher transforming potential in tumors of the anogenital tract. Therefore, in HNC, 
differential infection by HPV variants between races may also be an important area for 
investigation. 
At this time, we do not have sufficient understanding to offer a clear 
recommendation as to how to reduce oropharyngeal HPV infection or the risk of 
developing HPV+ oropharyngeal cancer. This appears to be a problem of environment 
and biology, without a reversible modifiable factor to reduce risk. We hope that greater 
adoption of HPV vaccination will alter the incidence curve within about 20 years. Our 
study has examined HPV and HNC, with a focus on oropharyngeal cancer. This study 
demonstrates that while HPV-related oropharyngeal cancer (HPV+/p16+) represents 
the majority cause among White patients, Blacks and Asians have lower rates. Because 
HPV-related oropharyngeal cancer has a more favorable outcome regardless of race, 
the differential HPV prevalence amongst Blacks and Asians is expected to cause a 
significant outcome disparity in oropharyngeal cancer treatment. Further studies 
specifically examining racial differences in HPV+oropharyngeal cancer are needed to 
corroborate these findings. However, this comprehensive pooled analysis of the 
published literature strongly supports a prevalence disparity in HPV+oropharyngeal 
cancer that would predict an outcome/survival disparity. 
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Table 1: Meta-Analysis of HPV Prevalence in Populations of African Descent 
Study 
HPV test 
Method HPV types detected N 
Any HPV 
N%, 95% CI 
HPV 16  
N%, 95% CI 
ALL HEAD AND NECK  
Van Rensburg et al. (1995)(40) ISH  66 0.0% (0.0-5.4) 0.0% (0.0-5.4) 
Gillison et al. (2000)(41) PCR 16, 18, 33, 31 48 20.8% (10.5-35.0)  
Boy et al. (2006)(42) PCR 16,18 21 9.5% (1.2-30.4) 0.0% (0.0-16.1) 
Argwal et al. (2008)(43) ISH 16 13 0.0% (0.0-24.7)  0.0% (0.0-24.7) 
Lewis et al. (2010)(44) ISH,PCR 16, 33 26 11.5% (2.4-30.1)  
Jalouli et al. (2012)(45) PCR X 20 65.0% (40.8-84.6)  
Jiron et al. (2013)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 161 24.8% (18.4-32.3) 20.5% (14.5-27.6) 
Stephen et al. (2012)(47) qRT-PCR 16 31 16.1% (5.4-33.7) 16.1% (5.4-33.7) 
Babiker et al. (2013)(48) PCR 16, 18, 33, 31 100 8.0% (3.5-15.2) 5.0% (1.6-11.3) 
Isayeva et al. (2014)(49)* qRT-PCR 16, 18 30 60.0% (40.6-77.3) 43.3% (25.5-62.6) 
Ndiaye C et al. (2013)(50) PCR 16,35,45 110 3.6% (1.0-9.0) 0.9% (0.0-5.0) 
Salazar et al. (2014)(51) PCR,RT-PCR 16 57 15.8% (7.5-27.9) 15.8% (7.5-27.9) 
Worsham et al. (2013)(10) q-PCR NR 49 30.6% (18.2-45.4) 30.6% (18.2-45.4) 
Isayeva et al. (2015)(52)* qRT-PCR 16, 18 22 22.7% (7.8-45.4) 13.6% (2.9-34.9) 
Liu et al. (2015)(26)* PCR 16 44  72.7% (57.2-85.0) 
TOTAL    798 17% (8.8-27.0) 13.7% (1.5-26.4) 
p value, Q test    0.000 0.000 
I2test    89.8% 93.8% 
p value, Egger’s test    0.419 0.643 
OROPHARYNX 
Lewis et al. (2010)(44) ISH,PCR 16, 33 26 11.5% (2.4-30.1)  
Jiron et al. (2012)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 36 25.0% (12.1-42.2)  
Isayeva et al. (2013)(49)* qRT-PCR 16, 18 30 60.0% (40.6-77.3) 43.3% (25.5-62.6) 
Salazar et al. (2013)(51) PCR,RT-PCR 16 23 34.8 (16.4-57.3) 34.8% (16.4-52.3) 
Worsham et al. (2013)(10) q-PCR NR 49 30.6% (18.2-45.4) 30.6% (18.2-45.4) 
Liu et al. (2015)(26)* PCR 16 44  72.7% (57.2-85.0) 
TOTAL    146 31.5% (17.7-47.1) 45.7% (25.5-66.6) 
p value, Q test    0.003 0.000 
I2test    75.5% 84.1% 
p value, Egger’s test    0.997 0.807 
NON-OROPHARYNX 
Van Rensburg et al. (1995)(40) ISH  66 0.0% (0.0-5.4) 0.0% (0.0-5.4) 
Boy et al. (2006)(42) PCR 16, 18 21 9.5% (1.2-30.4) 0.0% (0.0-16.1) 
Jalouli et al. (2012)(45) PCR X 20 65.0% (40.8-84.6)  
Jiron et al. (2013)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 125 24.8% (17.5-33.3)  
Ndiaye C et al. (2013)(50) PCR 16,35,45 105 3.8% (1.0-9.5) 1.0% (0.0-5.2) 
Isayeva et al. (2015)(52)* qRT-PCR 16,18 22  13.6% (2.9-34.9) 
TOTAL    337 14.5% (1.4-36.0) 1.1% (0.0-6.0) 
p value, Q test    0.000 0.048 
I2test    94.6% 62.1% 
p value, Egger’s test    0.685 0.424 
X: HPV genotype unknown; NR: Not reported; *Studies included in the pooled analysis 
Table 2: Description of studies included in the pooled-analysis 
 
*Pseudo datasets created from publication data; FFPE: Formalin-Fixed Paraffin Embedded tissue, FF - Fresh Frozen tissue, FT - Fresh Tissue; PCR - Polymerase Chain 
Reaction, RT-PCR, Real-time PCR (mRNA), HC2 - Hybrid Capture 2, ISH - in situ hybridization, IHC - Immunohistochemistry; A - African, AA - African American, AB - 
Aboriginal Australian, AS - Asian, W- White, UNK - unknown race;  O - Oropharynx, NO - Non-Oropharynx, UNKP - Unknown Primary; FU - Follow-up. 
 
Author (Year) 
Study 
size 
Tissue 
source 
HPV testing 
method 
p16 
expression 
Geographic 
region 
Race/ 
Ethnicity Tumor site 
FU, months 
(median) 
Cruz et al. (1996)(53)* 35 FF PCR -- Europe W NO -- 
Tsuhako et al. (2000)(54)* 88 FFPE PCR -- Asia AS NO , O -- 
Koskinen et al. (2003)(55)* 61 FF PCR -- Europe W NO , O -- 
De Petrini et al. (2006)(56) 70 FF PCR -- Europe W NO, O 30.4 
Ragin et al. (2006)(16) 125 FFPE PCR IHC US W NO, O 48.4 
Armas et al. (2008)(57;58) 280 FFPE PCR IHC Asia AS NO, O 18.6 
Cohen et al. (2008)(59)* 35 FFPE PCR -- US UNK O -- 
Worden et al. (2008)(60) 70 FFPE PCR -- US AA, W NO, O 13.5 
Szarka et al. (2005)(61) 33 FF PCR -- Europe W NO, O 25.4 
Szarka et al.2009(62) 55 FF PCR -- Europe W NO, O 77.4 
Straetmanset al. (2009)(63) 81 FFPE PCR/ISH IHC Europe W O -- 
Tachezy et al. (2009)(64) 135 FFPE PCR -- Europe W NO, O 47.7 
D’Souza et al. (2010)(65) 246 FFPE PCR/ISH -- US AA, AS, W NO, O 31.0 
Eng et al. (2010)(66) 15 FFPE PCR IHC US W NO, O 69.8 
Chernock et al. (2011)(8) 266 FFPE PCR/ISH IHC US AA, AS, W O -- 
Kabeya et al. (2012)(67)* 31 FF PCR IHC Asia AS NO -- 
Hoffman et al. (2012)(68)* 78 FF PCR IHC Europe W NO , O -- 
Park et al. (2012)(69) 89 FFPE PCR IHC Asia AS O 20.9 
Heusinkveld et al. (2012)(70)* 41 FFPE PCR -- Europe W NO, O -- 
Bussu et al. (2013, 2014)(71;72) 136 FT RT-PCR/HC2 IHC Europe A, W NO , O 12.5 
Isayeva et al. (2013; 2015)(52;73) 315 FFPE RT-PCR IHC US AA, AS, W NO, O 27.5 
Deng et al. (2013)(74;75) 131 FF PCR -- Asia AS NO, O 25.1 
Morbini et al. (2013)(76) 52 FFPE PCR/ISH IHC Europe W NO, O 50.5 
Hong et al. (2013)(77) 489 FFPE PCR IHC Australia W, AB, AS O 49.0 
Kruger et al. (2014)(12) 88 FF PCR -- Europe W NO -- 
Liu (2015)(26) 44 FFPE PCR IHC US AA O 18.9 
Morbini et al. (2015)(78) 41 FFPE PCR/ISH IHC Europe W O 21.2 
TOTAL 3,129       30.6 
Table 3: Adjusted prevalence of HPV16 and HPV18 according to race stratified by head and neck sub-site 
 N HPV16+ 
Mean Ageϕ 
(years ± SD) 
HPV16 
Prevalence† 
% (95% CI) 
N HPV18+ 
Mean Ageϕ 
(years, ± SD) 
HPV18 
Prevalence† 
N HPV16,18+ 
Mean Ageϕ 
(years, ± SD) 
HPV16,18 
Prevalence† 
All HNC 
Number of studies = 28 Number of studies = 24 Number of studies =28 
Asian 634 58.9 ± 0.64 28.4% (23.8-33.4) 631 61.9 ± 0.90 1.6% (0.7-3.9) 632 59.0 ± 0.68 26.0% (21.6-30.9) 
Black  158 56.6 ± 0.55 43.7% (34.2-53.8) 85 56.7 ± 0.20 9.8% (4.0-21.9) 131 56.7 ± 0.51 56.2% (45.1-66.7) 
White 2.123 56.5 ± 0.47 36.9% (34.0-40.0) 1,778 54.5 ± 0.50 1.6% (0.9-2.8) 1,915 56.6 ± 0.48 44.0% (40.8-47.3) 
Other* 58 55.3 ± 0.52 34.3% (16.2-58.5) 54 -- 7.7% (1.0-39.6) 58 55.3 ± 0.51 44.9% (23.1-68.8) 
   P=0.0123¥   P = 0.0077¥   P < 0.0001¥ 
TOTAL 2,973 56.8 ± 0.50  35.0% (32.8-37.2) 2,548 58.2 ± 0.70 1.9% (1.2-2.8) 2,736 56.9 ± 0.51 39.3% (37.1-41.7) 
Oropharynx 
Number of studies = 25 Number of studies = 21 Number of studies = 25 
Asian 433 56.8 ± 0.63 25.9% (21.1-31.4) 431 55.8 ± 1.02 1.6% (0.5-4.7) 432 56.7 ± 0.63 25.2% (20.5-30.7) 
Black  120 56.7 ± 0.58 51.1% (39.0-63.0) 65 57.0 ± 0.12  14.8% (5.6-33.7) 110 56.9 ± 0.54 58.0% (45.0-70.0) 
White 1,317 56.2 ± 0.46 57.3% (53.1-61.4) 1,100 56.5 ± 0.30 1.1% (0.4-2.5) 1,229 56.2 ± 0.46 61.1% (56.8-65.3) 
Other* 44 55.9 ± 0.49 74.1% (35.4-93.7) 42 -- -- 44 55.9 ± 0.48 74.1% (35.5-93.7) 
   
P < 0.0001¥ 
  
P = 0.0025¥ 
  
P < 0.0001¥ 
TOTAL 1,914 56.3 ± 0.49 46.6% (43.7-49.4) 1,638 56.4 ± 0.46 1.6% (1.0-2.7) 1,815 56.3 ± 0.48 48.7% (45.9-51.6) 
Non-Oropharynx 
Number of studies = 21 Number of studies = 19 Number of studies = 21 
Asian 201 65.0 ± 0.50  27.1% (16.4-41.4) 200 64.6 ± 0.80 -- 200 64.1 ± 0.64 20.9% (11.9-34.0) 
Black  38 54.6 ± 0.22 13.3% (5.0-30.8) 20 55.5 ± 0.90 3.2% (0.4-22.6)** 21 54.9 ± 0.31 30.2% (12.9-55.7) 
White 806 59.2 ± 0.52 11.3% (8.7-14.6) 678 51.9 ± 0.76 1.5% (0.6-3.8)** 686 58.7 ± 0.59 17.2% (13.5-21.5) 
Other* 14 -- 6.7% (0.9-37.0) 12 -- 11.6% (1.3-56.3)** 14 -- 18.4% (4.2-53.3) 
   
P = 0.0553¥ 
  
P =0.1434¥ 
  
P = 0.6344¥ 
TOTAL 1,059 60.5 ± 0.55 13.4% (11.0-16.3) 910 59.9 ± 0.88 1.4% (0.6-3.2)** 921 60.1 ± 0.63 18.2% (15.2-21.8) 
*Other includes other race/ethnic groups and unknown race; †Adjusted for each study, year of diagnosis, square root age, gender, alcohol, and smoking status; **smoking status 
predicted HPV18 perfectly and was excluded as a covariate; ¥Chi-square p-value for the differences between the four race/ethnic group categories; SD = Standard Deviation; ϕAge at 
diagnosis was back transformed after ANOVA using square root transformation. 
Table 4: Predictors of overall survival (all-cause mortality) for oropharyngeal cancer patients according to 
smoking status and race 
All-cause mortality HR, 95% CI*   
Oropharynx 
All Races 
(N = 880) 
All Races 
Ever Smokers 
(n = 746) 
All Races 
Never Smokers 
(n = 134) 
White  
(n = 475) 
Non-White  
(n = 401) 
Stage 0/I/II 
(n = 149) 
Stage III/IV 
(n = 731) 
Race 
     White 
     Asian 
     Black 
     Other 
 
Age at diagnosis 
 
Smoking 
     Never smoker 
     Ever smoker 
 
Alcohol 
     Never drinker 
     Ever drinker 
 
Sex 
     Male 
     Female 
 
Stage 
    0/I/II 
    III/IV 
 
HPV/p16 status 
  HPV16,18+/p16+ 
  HPV16,18-/p16+ 
  HPV16,18+/p16- 
  HPV16,18-/p16- 
 
 
Ref (1.00) 
0.87 (0.56-1.37) 
0.85 (0.50-1.45) 
0.57 (0.08-4.15) 
 
1.25 (1.09-1.44) 
 
 
Ref (1.00) 
1.95 (1.34-2.83) 
 
 
Ref (1.00) 
1.00 (0.80-1.26) 
 
 
Ref (1.00) 
0.74 (0.54-1.01) 
 
 
Ref (1.00) 
2.08 (1.56-2.77) 
 
 
Ref (1.00) 
1.88 (1.19-2.97) 
3.24 (2.25-4.66) 
3.17 (2.39-4.20) 
 
Ref (1.00) 
0.80 (0.50-1.28) 
0.78 (0.45-1.37) 
-- 
 
1.23 (1.06-1.42) 
 
 
 
 
 
 
Ref (1.00) 
0.96 (0.76-1.22) 
 
 
Ref (1.00) 
0.74 (0.53-1.05) 
 
 
Ref (1.00) 
2.15 (1.59-2.90) 
 
 
Ref (1.00) 
1.82 (1.09-3.03) 
3.41 (2.32-5.01) 
3.30 (2.43-4.47) 
 
Ref (1.00) 
1.27 (0.27-5.91) 
2.14 (0.19-24.08) 
3.99 (0.46-34.18) 
 
1.47(0.90-2.39) 
 
 
 
 
 
 
Ref (1.00) 
1.45 (0.65-3.23) 
 
 
Ref (1.00) 
0.69 (0.30-1.61) 
 
 
Ref (1.00) 
1.83 (0.64-5.23) 
 
 
Ref (1.00) 
2.29 (0.74-7.08) 
2.19 (0.57-8.44) 
2.70 (1.12-6.51) 
 
 
 
 
 
 
1.75 (1.39-2.21) 
 
 
Ref (1.00) 
1.70 (0.99-2.93) 
 
 
Ref (1.00) 
1.46 (0.92-2.34) 
 
 
Ref (1.00) 
0.70 (0.49-1.01) 
 
 
Ref (1.00) 
2.20 (1.53-3.16) 
 
 
Ref (1.00) 
2.91 (1.72-4.92) 
3.30 (2.09-5.21) 
2.82 (1.94-4.10) 
 
 
 
 
 
 
1.00 (0.89-1.26) 
 
 
Ref (1.00) 
1.87 (1.11-3.17) 
 
 
Ref (1.00) 
0.89 (0.67-1.20) 
 
 
Ref (1.00) 
0.87 (0.48-1.59) 
 
 
Ref (1.00) 
2.13 (1.27-3.55) 
 
 
Ref (1.00) 
0.69 (0.24-2.01) 
2.95 (1.60-5.42) 
3.11 (1.97-4.92) 
 
Ref (1.00) 
2.54 (0.73-8.78) 
1.47 (0.27-7.82) 
-- 
 
1.45 (0.93-2.26) 
 
 
Ref (1.00) 
2.58 (0.79-8.46) 
 
 
Ref (1.00) 
1.06 (0.51-2.22) 
 
 
Ref (1.00) 
0.36 (0.16-0.81) 
 
 
 
 
 
 
Ref (1.00) 
7.96 (2.08-30.43) 
7.22 (2.26-23.11) 
4.36 (1.51-12.60) 
 
Ref (1.00) 
0.67 (0.41-1.11) 
0.71 (0.40-1.28) 
-- 
 
1.24 (1.07-1.43) 
 
 
Ref (1.00) 
2.08 (1.39-3.11) 
 
 
Ref (1.00) 
1.00 (0.79-1.28) 
 
 
Ref (1.00) 
0.87 (0.62-1.23) 
 
 
 
 
 
 
Ref (1.00) 
1.58 (0.95-2.63) 
2.85 (1.91-4.25) 
3.07 (2.28-4.13) 
*Covariates included: square root age, year of diagnosis, race, sex, smoking, alcohol, stage at diagnosis combined HPV16,18 and p16 status and study 
 
 
 Table 5: Risk of disease progression for oropharyngeal cancer patients according to HPV/p16 status and race  
 
Disease persistence and/or recurrence HR, 
95% CI* 
HPV/p16 status 
White 
N = 475 
Non-White 
N = 401 
 
HPV16,18+/p16+ 
HPV16,18-/p16+ 
HPV16,18+/p16- 
HPV16,18-/p16- 
 
Ref (1.00) 
2.33 (1.22-4.45) 
3.62 (2.21-5.95) 
3.23 (2.14-4.88) 
 
Ref (1.00) 
0.52 (0.12-2.27) 
1.44 (0.58-3.61) 
2.70 (1.52-4.82) 
 
Metastasis HR, 95% CI* 
HPV16,18+/p16+ 
HPV16,18-/p16+ 
HPV16,18+/p16- 
HPV16,18-/p16- 
Ref (1.00) 
1.84 (0.49-6.90) 
2.61 (0.90-7.51) 
2.08 (0.88-4.91) 
Ref (1.00) 
0.81 (0.35-1.88) 
1.08 (0.48-2.42) 
1.94 (1.26-2.99) 
*Adjusted for year of diagnosis, square root age, sex, race, stage, smoking, alcohol and study 
 
 
 
 
 
 
 
 
Figure Legends 
 
Figure 1: Flow diagram of study selection 
Figure 2: Proportions of combined HPV16,18 and p16 status among all (A), ever 
smoker (B) and never smoker (C) oropharynx cancer patients stratified by race 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 1: Meta-Analysis of HPV Prevalence in Populations of African Descent, Stratified by Geographic 
Region and HPV Test Method 
Study 
HPV test 
Method HPV types detected N 
Any HPV 
N%, 95% CI 
HPV 16  
N%, 95% CI 
ALL HEAD AND NECK  
SUB-SAHARAN AFRICA 
 
 
   
Van Rensburg et al. (1995)(40) ISH  66 0.0% (0.0-5.4) 0.0% (0.0-5.4) 
Boy et al. (2006)(42) PCR 16,18 21 9.5% (1.2-30.4) 0.0% (0.0-16.1) 
Jalouli et al. (2012)(45) PCR X 20 65.0% (40.8-84.6)  
Babiker et al. (2013)(48) PCR 16, 18, 33, 31 100 8.0% (3.5-15.2) 5.0% (1.6-11.3) 
Ndiaye C et al. (2013)(50) PCR 16, 35, 45 110 3.6% (1.0-9.0) 0.9% (0.0-5.0) 
TOTAL    317 10.7% (1.0-27.2) 1.0% (0.0-3.9) 
p value, Q test    0.000 0.129 
I2test    92.0% 47.0% 
p value, Egger’s test    0.600 0.686 
 
     
PCR methods only      
Boy et al. (2006)(42) PCR 16,18 21 9.5% (1.2-30.4) 0.0% (0.0-16.1) 
Jalouli et al. (2012)(45) PCR X 20 65.0% (40.8-84.6)  
Babiker et al. (2013)(48) PCR 16, 18, 33, 31 100 8.0% (3.5-15.2) 5.0% (1.6-11.3) 
Ndiaye C et al. (2013)(50) PCR 16, 35, 45 110 3.6% (1.0-9.0) 0.9% (0.0-5.0) 
TOTAL    251 16.2% (2.3-37.7) 1.7% (0.0-5.4) 
p value, Q test    0.000 0.184 
I2test    91.9% 40.9% 
USA 
 
 
   
Gillison et al. (2000)(41) PCR 16, 18, 33, 31 48 20.8% (10.5-35.0)  
Argwal et al. (2008)(43) ISH 16 13 0.0% (0.0-24.7)  0.0% (0.0-24.7) 
Lewis et al. (2010)(44) ISH,PCR 16, 33 26 11.5% (2.4-30.1)  
Jiron et al. (2013)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 161 24.8% (18.4-32.3) 20.5% (14.5-27.6) 
Stephen et al. (2012)(47) qRT-PCR 16 31 16.1% (5.4-33.7) 16.1% (5.4-33.7) 
Isayeva et al. (2014)(49)* qRT-PCR 16, 18 30 60.0% (40.6-77.3) 43.3% (25.5-62.6) 
Salazar et al. (2014)(51) PCR,RT-PCR 16 57 15.8% (7.5-27.9) 15.8% (7.5-27.9) 
Worsham et al. (2013)(10) q-PCR NR 49 30.6% (18.2-45.4) 30.6% (18.2-45.4) 
Isayeva et al. (2015)(52)* qRT-PCR 16, 18 22 22.7% (7.8-45.4) 13.6% (2.9-34.9) 
Liu et al. (2015)(26)* PCR 16 44  72.7% (57.2-85.0) 
TOTAL    798 21.7% (13.7-30.8) 25.0% (12.3-40.2) 
p value, Q test    0.000 0.000 
I2test    74.3% 89.0% 
p value, Egger’s test    0.249 0.967 
 
     
PCR methods only      
Gillison et al. (2000)(41) PCR 16, 18, 33, 31 48 20.8% (10.5-35.0)  
Jiron et al. (2013)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 161 24.8% (18.4-32.3) 20.5% (14.5-27.6) 
Stephen et al. (2012)(47) qRT-PCR 16 31 16.1% (5.4-33.7) 16.1% (5.4-33.7) 
Isayeva et al. (2014)(49)* qRT-PCR 16, 18 30 60.0% (40.6-77.3) 43.3% (25.5-62.6) 
Salazar et al. (2014)(51) PCR,RT-PCR 16 57 15.8% (7.5-27.9) 15.8% (7.5-27.9) 
Worsham et al. (2013)(10) q-PCR NR 49 30.6% (18.2-45.4) 30.6% (18.2-45.4) 
Isayeva et al. (2015)(52)* qRT-PCR 16, 18 22 22.7% (7.8-45.4) 13.6% (2.9-34.9) 
Liu et al. (2015)(26)* PCR 16 44  72.7% (57.2-85.0) 
TOTAL     26% (17.7-35.3) 29.4% (15.8-45.0) 
p value, Q test    0.002 0.000 
I2test    71.1% 89.0% 
OROPHARYNX 
USA 
     
Lewis et al. (2010)(44) ISH,PCR 16, 33 26 11.5% (2.4-30.1)  
Jiron et al. (2012)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 36 25.0% (12.1-42.2)  
Isayeva et al. (2013) (49)* qRT-PCR 16, 18 30 60.0% (40.6-77.3) 43.3% (25.5-62.6) 
Salazar et al. (2013)(51) PCR,RT-PCR 16 23 34.8 (16.4-57.3) 34.8% (16.4-52.3) 
Worsham et al. (2013)(10) q-PCR NR 49 30.6% (18.2-45.4) 30.6% (18.2-45.4) 
Liu et al. (2015)(26)* PCR 16 44  72.7% (57.2-85.0) 
TOTAL    146 31.5% (17.7-47.1) 45.7% (25.5-66.6) 
p value, Q test    0.003 0.000 
I2test    75.5% 84.1% 
p value, Egger’s test    0.997 0.807 
 
     
PCR methods only      
Jiron et al. (2012)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 36 25.0% (12.1-42.2)  
Isayeva et al. (2013) (49)* qRT-PCR 16, 18 30 60.0% (40.6-77.3) 43.3% (25.5-62.6) 
Salazar et al. (2013)(51) PCR,RT-PCR 16 23 34.8 (16.4-57.3) 34.8% (16.4-52.3) 
Worsham et al. (2013)(10) q-PCR NR 49 30.6% (18.2-45.4) 30.6% (18.2-45.4) 
Liu et al. (2015)(26)* PCR 16 44  72.7% (57.2-85.0) 
TOTAL    182 36.9% (22.8-52.1) 45.7% (25.5-66.6) 
p value, Q test    0.025 0.000 
I2test    68% 84.1% 
NON-OROPHARYNX 
SUB-SAHARAN AFRICA 
     
Van Rensburg et al. (1995)(40) ISH  66 0.0% (0.0-5.4) 0.0% (0.0-5.4) 
Boy et al. (2006)(42) PCR 16, 18 21 9.5% (1.2-30.4) 0.0% (0.0-16.1) 
Jalouli et al. (2012)(45) PCR X 20 65.0% (40.8-84.6)  
Ndiaye C et al. (2013)(50) PCR 16,35,45 105 3.8% (1.0-9.5) 1.0% (0.0-5.2) 
TOTAL    212 12.2% (0.0-38.1) 0.1% (0.0-1.8) 
p value, Q test    0.000 0.768 
I2test    93.9% 0.0% 
p value, Egger’s test    0.280 0.881 
 
     
PCR methods only      
Boy et al. (2006)(42) PCR 16, 18 21 9.5% (1.2-30.4) 0.0% (0.0-16.1) 
Jalouli et al. (2012)(45) PCR X 20 65.0% (40.8-84.6)  
Ndiaye C et al. (2013)(50) PCR 16,35,45 105 3.8% (1.0-9.5) 1.0% (0.0-5.2) 
TOTAL    146 20.8% (0.0-62.3) 0.3% (0.0-2.9) 
p value, Q test    0.000 0.932 
I2test    94.4% 0.0% 
USA 
 
 
   
Jiron et al. (2013)(46) PCR 6,33,11,16,18,31,52,35,45,51,56 125 24.8% (17.5-33.3)  
Isayeva et al. (2015)(52)* qRT-PCR 16,18 22  13.6% (2.9-34.9) 
TOTAL    337   
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2: Adjusted prevalence of HPV16 and HPV18 according to race stratified by head and neck 
sub-site with regression coefficients and standard errors. 
 HPV16 
 
HPV18 
 
HPV16,18 
Coefficient Standard Error  Prevalence† Coefficient Standard Error Prevalence† Coefficient Standard Error Prevalence† 
All HNC 
Number of studies = 28 Number of studies = 24 Number of studies =28 
Asian -0.391 0.148 28.4% (23.8-33.4)  0.021 0.598 1.6% (0.7-3.9)  -0.808 0.155 26.0% (21.6-30.9) 
Black  0.283 0.219 43.7% (34.2-53.8)  1.902 0.532 9.8% (4.0-21.9)  0.490 0.241 56.2% (45.1-66.7) 
White (reference) -- 36.9% (34.0-40.0)  (reference) -- 1.6% (0.9-2.8)  (reference) -- 44.0% (40.8-47.3) 
Other* -0.117 0.511 34.3% (16.2-58.5)  1.644 1.084 7.7% (1.0-39.6)    0.033 0.513 44.9% (23.1-68.8) 
   P=0.0123¥    P = 0.0077¥    P < 0.0001¥ 
TOTAL   35.0% (32.8-37.2)    1.9% (1.2-2.8)    39.3% (37.1-41.7) 
Oropharynx 
Number of studies = 25 Number of studies = 21 Number of studies = 25 
Asian -1.344 0.182 25.9% (21.1-31.4)  0.372 0.828 1.6% (0.5-4.7)  -1.540 0.189 25.2% (20.5-30.7) 
Black  -0.252 0.271 51.1% (39.0-63.0)  2.769 0.682 14.8% (5.6-33.7)  -0.129 0.290 58.0% (45.0-70.0) 
White (reference) -- 57.3% (53.1-61.4)  (reference) -- 1.1% (0.4-2.5)  (reference) -- 61.1% (56.8-65.3) 
Other* 0.758 0.846 74.1% (35.4-93.7)  -- -- --  0.598 0.845 74.1% (35.5-93.7) 
   
P < 0.0001¥ 
   
P = 0.0025¥ 
   
P < 0.0001¥ 
TOTAL   46.6% (43.7-49.4)    1.6% (1.0-2.7)    48.7% (45.9-51.6) 
Non-Oropharynx 
Number of studies = 21 Number of studies = 19 Number of studies = 21 
Asian 1.069 0.397 27.1% (16.4-41.4)    --  0.241 0.401 20.9% (11.9-34.0) 
Black  0.183 0.571 13.3% (5.0-30.8)  0.784 1.133 3.2% (0.4-22.6)**  0.735 0.568 30.2% (12.9-55.7) 
White (reference) -- 11.3% (8.7-14.6)  (reference) -- 1.5% (0.6-3.8)**  (reference) -- 17.2% (13.5-21.5) 
Other* -0.569 1.073 6.7% (0.9-37.0)  2.155 1.209 11.6% (1.3-56.3)**  0.083 0.834 18.4% (4.2-53.3) 
   
P = 0.0553¥ 
   
P = 0.1434¥ 
   
P = 0.6344¥ 
TOTAL   13.4% (11.0-16.3)    1.4% (0.6-3.2)**    18.2% (15.2-21.8) 
*Other includes other race/ethnic groups and unknown race; †Adjusted for each study, year of diagnosis, square root age, gender, alcohol, and smoking status; **smoking status 
predicted HPV18 perfectly and was excluded as a covariate; ¥Chi-square p-value for the differences between the four race/ethnic group categorie 
